Robert Mashal, serving as a director at Nuvation Bio Inc. (NASDAQ:NUVB), has executed a notable acquisition of the company's Class A Common Stock. The transaction, which took place on June 9, 2026, involved the purchase of 25,000 shares. According to a recent Securities and Exchange Commission (SEC) filing, Mashal acquired these shares at a price of $4.73 per share, bringing the total value of the transaction to $118,250.
The shares were not purchased directly by Mashal but were acquired indirectly through the Robert D. Mashal 2020 Revocable Trust, for which he serves as the sole trustee. Following this acquisition, Mashal's total indirect ownership stake in Nuvation Bio has increased to 225,000 shares. This insider activity occurs as NUVB shares trade near the $4.76 mark. Market analysis suggests that the stock is currently trading at a discount relative to its calculated Fair Value, positioning it among the most undervalued opportunities in the current market landscape. Despite experiencing recent volatility, the stock has delivered a substantial 163% return over the past year.
Nuvation Bio's financial performance provides context to the timing of this insider purchase. The company reported its first-quarter 2026 earnings, with revenue significantly exceeding analyst expectations. Nuvation Bio posted revenue of $83.2 million, surpassing the forecasted $66.2 million by 25.69%. Earnings per share matched analysts' forecasts at $0.01. In addition to financial results, the company has advanced its operational capabilities through a strategic partnership with Thermo Fisher Scientific for the manufacturing of IBTROZI in the United States. The company has completed the process technology transfer and product introduction for this collaboration. This transition was submitted as a supplement to the existing New Drug Application for IBTROZI, which is approved for treating advanced ROS1-positive non-small cell lung cancer.
Furthermore, Nuvation Bio presented patient-reported outcomes data from the TRUST-II study of IBTROZI at the American Society of Clinical Oncology Annual Meeting. The data indicated that 88% of patients reported improved or stable global health quality-of-life scores. Market sentiment regarding the company remains positive, with RBC Capital reiterating an Outperform rating on Nuvation Bio. The firm has maintained a $20.00 price target on the stock. This rating comes following GSK's proposed acquisition of competitor Nuvularia, an event that highlights the continued perceived value in the ROS1 market. Nuvation Bio's stock closed at 4.76, reflecting a +0.180 change (+3.93%), with after-hours trading showing a slight increase to 4.78.